NAS:ORGO (USA)
Â
Class A
$
4.56
+0.030 (+0.66%)
11:08 PM EST
Warning! GuruFocus detected
1 Severe warning sign
with ORGO.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Current and historical daily PE Ratio for Organogenesis Holdings Inc (
) from 2016 to Apr 27 2025. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Organogenesis stock (ORGO) PE ratio as of Apr 27 2025 is 0.
More Details
Organogenesis Holdings Inc (ORGO) PE Ratio (TTM) Chart
Organogenesis Holdings Inc (ORGO) PE Ratio (TTM) Historical Data
View and export this data going back to 2016. Start your Free Trial
Total 1214
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Organogenesis PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2025-04-27 | At Loss | 2025-02-21 | At Loss |
| 2025-04-25 | At Loss | 2025-02-20 | At Loss |
| 2025-04-24 | At Loss | 2025-02-19 | At Loss |
| 2025-04-23 | At Loss | 2025-02-18 | At Loss |
| 2025-04-22 | At Loss | 2025-02-14 | At Loss |
| 2025-04-21 | At Loss | 2025-02-13 | At Loss |
| 2025-04-17 | At Loss | 2025-02-12 | At Loss |
| 2025-04-16 | At Loss | 2025-02-11 | At Loss |
| 2025-04-15 | At Loss | 2025-02-10 | At Loss |
| 2025-04-14 | At Loss | 2025-02-07 | At Loss |
| 2025-04-11 | At Loss | 2025-02-06 | At Loss |
| 2025-04-10 | At Loss | 2025-02-05 | At Loss |
| 2025-04-09 | At Loss | 2025-02-04 | At Loss |
| 2025-04-08 | At Loss | 2025-02-03 | At Loss |
| 2025-04-07 | At Loss | 2025-01-31 | At Loss |
| 2025-04-04 | At Loss | 2025-01-30 | At Loss |
| 2025-04-03 | At Loss | 2025-01-29 | At Loss |
| 2025-04-02 | At Loss | 2025-01-28 | At Loss |
| 2025-04-01 | At Loss | 2025-01-27 | At Loss |
| 2025-03-31 | At Loss | 2025-01-24 | At Loss |
| 2025-03-28 | At Loss | 2025-01-23 | At Loss |
| 2025-03-27 | At Loss | 2025-01-22 | At Loss |
| 2025-03-26 | At Loss | 2025-01-21 | At Loss |
| 2025-03-25 | At Loss | 2025-01-17 | At Loss |
| 2025-03-24 | At Loss | 2025-01-16 | At Loss |
| 2025-03-21 | At Loss | 2025-01-15 | At Loss |
| 2025-03-20 | At Loss | 2025-01-14 | At Loss |
| 2025-03-19 | At Loss | 2025-01-13 | At Loss |
| 2025-03-18 | At Loss | 2025-01-10 | At Loss |
| 2025-03-17 | At Loss | 2025-01-08 | At Loss |
| 2025-03-14 | At Loss | 2025-01-07 | At Loss |
| 2025-03-13 | At Loss | 2025-01-06 | At Loss |
| 2025-03-12 | At Loss | 2025-01-03 | At Loss |
| 2025-03-11 | At Loss | 2025-01-02 | At Loss |
| 2025-03-10 | At Loss | 2024-12-31 | At Loss |
| 2025-03-07 | At Loss | 2024-12-30 | At Loss |
| 2025-03-06 | At Loss | 2024-12-27 | At Loss |
| 2025-03-05 | At Loss | 2024-12-26 | At Loss |
| 2025-03-04 | At Loss | 2024-12-24 | At Loss |
| 2025-03-03 | At Loss | 2024-12-23 | At Loss |
| 2025-02-28 | At Loss | 2024-12-20 | At Loss |
| 2025-02-27 | At Loss | 2024-12-19 | At Loss |
| 2025-02-26 | At Loss | 2024-12-18 | At Loss |
| 2025-02-25 | At Loss | 2024-12-17 | At Loss |
| 2025-02-24 | At Loss | 2024-12-16 | At Loss |
Organogenesis Holdings Inc (ORGO) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Organogenesis Holdings Inc
NAICS : 325412
SIC : 2834
ISIN : US68621F1021
Share Class Description:
ORGO: Class ACompare
Compare
Traded in other countries / regions
ORGO.USA2PQ.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2016-11-29Description
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers